Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Deutsches Krebsforschungszentrum

Medigene Ag

Faulstich, Heinz, Dr.

Sandra Lüttgau

Gerhard Moldenhauer

Peter Altevogt

Yi Li

Frank Breitling

Annemarie Poustka

Daniela Kelm

Susanne Sebens

Frank Brietling

Heinz Faulstich

John Hazin

Thorsten Kühlwein

Achim Krüger

Silke Bärreiter

Ulrich Möbius

Heiner Schäfer

The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.

Binding molecules, especially antibodies, binding to L1CAM (CD171)

The invention relates to a method for the production of a protein library, in particular an antibody library, which is highly diverse and for the selection of proteins, in particular antibodies, therefrom.

Method for producing protein libraries and for selecting proteins from said libraries

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.

Treatment of tumors using specific anti-L1 antibody

Growing community of inventors

Schongau, Germany

Sandra Lüttgau